Atea Pharmaceuticals Inc (OQ:AVIR)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 07, 2024 07:00 am ET

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference...

Apr 29, 2024 07:00 am ET

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data...

Mar 27, 2024 07:00 am ET

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Feb 28, 2024 04:05 pm ET

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the...

Feb 21, 2024 07:00 am ET

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Jan 08, 2024 04:05 pm ET

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Jan 03, 2024 07:00 am ET

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023 07:00 am ET

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Nov 08, 2023 04:05 pm ET

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for...

Nov 08, 2023 07:00 am ET

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Nov 02, 2023 07:00 am ET

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced two upcoming poster presentations at...

Nov 01, 2023 07:00 am ET

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Sep 06, 2023 07:00 am ET

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 08, 2023 04:05 pm ET

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 01, 2023 07:00 am ET

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Jun 15, 2023 07:00 am ET

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Jun 05, 2023 04:20 pm ET

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 30, 2023 07:00 am ET

Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

May 23, 2023 04:05 pm ET

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash,...

May 08, 2023 04:05 pm ET

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 01, 2023 04:05 pm ET

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

Apr 25, 2023 07:00 am ET

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Apr 12, 2023 07:00 am ET

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of the full...

Mar 14, 2023 07:00 am ET

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research

Mar 08, 2023 07:00 am ET

New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentations at the...

Feb 28, 2023 04:05 pm ET

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “This year, we are...

Feb 23, 2023 07:00 am ET

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment is needed for CYP3A...

Feb 21, 2023 07:00 am ET

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results...

Feb 15, 2023 04:05 pm ET

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place February...

Feb 07, 2023 07:00 am ET

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team,...

Jan 09, 2023 07:00 am ET

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today provided an update on the company’s clinical development programs for 2023, including its strategic priorities and expectations for achievement of...

Jan 04, 2023 07:00 am ET

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the...

Nov 29, 2022 07:00 am ET

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the SUNRISE-3 Phase 3 trial, a global multicenter trial evaluating bemnifosbuvir (AT-527) for...

Nov 22, 2022 07:00 am ET

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea...

Nov 08, 2022 04:05 pm ET

Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will participate in and present a...

Nov 07, 2022 04:05 pm ET

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022 and provided a business update. “This year, we have made substantial...

Nov 03, 2022 07:00 am ET

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue fever at the American Society of Tropical...

Oct 31, 2022 07:00 am ET

Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report financial results for...

Sep 26, 2022 07:00 am ET

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AT-752, a novel, orally administered,...

Sep 13, 2022 07:00 am ET

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced additional details on its clinical development plans for bemnifosbuvir for the treatment of COVID-19. Following meetings with the U.S....

Sep 07, 2022 07:00 am ET

Atea Pharmaceuticals Announces Upcoming Investor Events

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in the following investor events in September. Bemnifosbuvir Global Phase 3 Registrational...

Aug 08, 2022 04:05 pm ET

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “COVID-19 continues to be a global...

Aug 01, 2022 07:00 am ET

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for...

Jul 11, 2022 07:00 am ET

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals together with other members of the Atea...

Jun 01, 2022 07:00 am ET

Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overview and...

May 10, 2022 06:30 am ET

Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. “We are very pleased to report new...

May 03, 2022 04:05 pm ET

Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to report financial results for the...

Mar 28, 2022 07:00 am ET

Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data demonstrating the nonclinical safety of bemnifosbuvir (AT-527) at the Society of Toxicology...

Mar 01, 2022 07:35 am ET

Thinking about buying stock in CTI BioPharma, 3D Systems, Atea Pharmaceuticals, Editas Medicine, or Mullen Automotive?

NEW YORK, March 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTIC, DDD, AVIR, EDIT, and MULN.

Feb 28, 2022 04:05 pm ET

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “During 2022, we...

Feb 22, 2022 07:00 am ET

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report financial results for...

Feb 10, 2022 07:00 am ET

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as...

Feb 09, 2022 07:00 am ET

Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced that Jean-Pierre Sommadossi,...

Feb 02, 2022 07:00 am ET

Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir (AT-527) were published in the peer-reviewed journal, Nature Communications, in an article...

Feb 01, 2022 06:39 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....

Jan 27, 2022 09:30 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. ("Atea" or the "Company") (NASDAQ: AVIR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jan 23, 2022 01:11 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

Jan 17, 2022 07:29 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

NEW YORK, Jan. 17, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. ("Atea" or the "Company") (NASDAQ: AVIR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jan 13, 2022 08:35 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

Jan 12, 2022 03:44 pm ET

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Investors who purchased Atea shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bg

Jan 07, 2022 01:02 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIR

NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. ("Atea" or the "Company") (NASDAQ: AVIR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jan 07, 2022 07:00 am ET

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today provided an update on the company’s clinical development priorities for 2022, including broadening its portfolio to include Phase 2 programs...

Jan 03, 2022 07:00 am ET

Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present at the 40th Annual J.P....

Dec 17, 2021 07:00 am ET

Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021....

Dec 14, 2021 04:30 pm ET

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced an updated strategy for AT-527 to address the rapidly evolving SARS-CoV-2 and emerging variants by maximizing the compound’s unique...

Nov 22, 2021 07:00 am ET

Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th...

Nov 16, 2021 04:30 pm ET

Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be...

Nov 11, 2021 04:01 pm ET

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update. Key highlights of today’s...

Nov 04, 2021 07:53 am ET

Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. ET to report financial results...

Oct 19, 2021 10:45 am ET

Thinking about buying stock in Progenity, Atea Pharmaceuticals, Peabody Energy, Adamis Pharmaceuticals, or Ion Geophysical?

NEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PROG, AVIR, BTU, ADMP, and IO.

Oct 19, 2021 07:00 am ET

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported that the global Phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting did not meet the primary endpoint of reduction from...

Oct 07, 2021 07:00 am ET

Atea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will present analyses confirming data previously reported relating to the AT-527 COVID-19 clinical trial program at the...

Oct 04, 2021 09:31 am ET

Thinking about buying stock in Xenon Pharmaceuticals, Meritor, RedHill Biopharma, Atea Pharmaceuticals, or Falcon Minerals?

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XENE, MTOR, RDHL, AVIR, and FLMN.

Oct 01, 2021 09:31 am ET

Thinking about trading options or stock in Carnival Corp, Atea Pharmaceuticals, AMC Entertainment, Merck, or Delta Air?

NEW YORK, Oct. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CCL, AVIR, AMC, MRK, and DAL.

Sep 29, 2021 07:00 am ET

Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team,...

Sep 07, 2021 07:00 am ET

Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team,...

Aug 24, 2021 07:00 am ET

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal,...

Aug 12, 2021 04:05 pm ET

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update. “We are very encouraged...

Aug 05, 2021 07:00 am ET

Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for...

Jul 12, 2021 07:00 am ET

Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder,...

Jun 30, 2021 09:31 am ET

Thinking about buying stock in Dare Bioscience, Powerbridge Technologies, Atea Pharmaceuticals, Ammo Inc, or Eloxx Pharmaceuticals?

NEW YORK, June 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, PBTS, AVIR, POWW, and ELOX.

Jun 30, 2021 07:00 am ET

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced positive interim results from the global Phase 2 study evaluating...

Jun 16, 2021 07:00 am ET

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

Jun 15, 2021 07:00 am ET

Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice...

May 26, 2021 07:00 am ET

Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

May 20, 2021 07:00 am ET

Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors....

May 13, 2021 04:05 pm ET

Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended March 31, 2021 and provided a corporate update. “Over the course of a year, we have gone from...

May 06, 2021 07:00 am ET

Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 13, 2021 at 4:30 p.m. ET to report financial results for the...

Apr 29, 2021 02:00 am ET

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild or moderate...

Mar 30, 2021 04:01 pm ET

Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the year ended December 31, 2020 and provided a corporate update. “For Atea, 2020 was a transformational year that...

Mar 23, 2021 07:00 am ET

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial results for...

Mar 06, 2021 07:00 am ET

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented results from the Phase 1 study of AT-527 in healthy volunteers at the 28th Annual Conference on Retroviruses and Opportunistic...

Feb 19, 2021 08:30 am ET

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has in-licensed the rights for AT-527 for the treatment of COVID-19 in Japan from...

Feb 08, 2021 04:01 pm ET

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is an orally...

Feb 04, 2021 07:00 am ET

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an...

Jan 19, 2021 07:00 am ET

Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has expanded its senior management team with the appointments of Jayanthi Wolf, Ph.D., Senior Vice President of Regulatory...

Dec 21, 2020 07:00 am ET

Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral...

Dec 18, 2020 08:00 am ET

Atea Pharmaceuticals Added to Russell 2000 Index

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000® Index, effective December 21, 2020, as part of the index's quarterly initial public offering...

Nov 25, 2020 07:00 am ET

Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Nov 06, 2020 08:00 am ET

Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan

Nov 03, 2020 04:01 pm ET

Atea Pharmaceuticals Announces Closing of Initial Public Offering

Oct 29, 2020 08:00 pm ET

Atea Pharmaceuticals Announces Pricing of Initial Public Offering

Feb 09, 2018 03:30 pm ET

Vaxart Provides Merger Update

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it has reached an understanding with the CAS Group under which East Hill, a major shareholder in Aviragen, will support the merger between Vaxart and Aviragen.

Feb 09, 2018 02:00 pm ET

Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms

CAS Group Supports Improved DealCompany Currently has Sufficient Votes to Approve Merger

Feb 09, 2018 01:29 pm ET

CAS Group Supports Improved Vaxart Merger and Enters Into Agreement With Aviragen

SUWANEE, Ga. and PETERBOROUGH, N.H., Feb. 9, 2018 /PRNewswire/ -- Digirad Corporation, East Hill Management Company, LLC, and Thomas M. Clay (collectively with certain other participants in the solicitation, the "Concerned Aviragen Shareholders Group", the "CAS Group", "we" or "us"), who are significant stockholders of Aviragen Therapeutics, Inc., a Delaware corporation ("Aviragen", "AVIR" or the "Company") (NASDAQ: AVIR), with collective beneficial ownership of approximately 8.3% of AVIR's outstanding shares of common stock (the "Common Stock"), today announced that it has carefully reviewe

Feb 07, 2018 03:22 pm ET

Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders

Aviragen Stockholders to Own 49% of Combined Company, Up from 40% Under the Previous Agreement

Feb 06, 2018 10:25 am ET

Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018

Board of Directors Unanimously Recommends that Aviragen Stockholders Vote FOR the Vaxart Merger

Jan 31, 2018 06:15 pm ET

Aviragen Provides New Information Supporting Vote FOR Vaxart Merger

Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders

Jan 31, 2018 08:00 am ET

CAS Group Announces Glass Lewis Recommendation That Aviragen Stockholders Vote AGAINST Merger and Emphasizes Value of Teslexivir (BTA074) Program

SUWANEE, Ga. and PETERBOROUGH, N.H., Jan. 31, 2018 /PRNewswire/ -- Digirad Corporation, East Hill Management Company, LLC, and Thomas M. Clay (collectively with certain other participants in the solicitation, the "Concerned Aviragen Shareholders Group", the "CAS Group", "we" or "us"), who are significant stockholders of Aviragen Therapeutics, Inc., a Delaware corporation ("Aviragen", "AVIR" or the "Company") (NASDAQ: AVIR), with collective beneficial ownership of approximately 8.3% of AVIR's outstanding shares of common stock, today wish to emphasize the potential value of the Company's ongo

Jan 29, 2018 08:11 am ET

ISS Recommends Aviragen Stockholders Vote AGAINST the Vaxart Merger on the CAS Group's BLUE Proxy Card

SUWANEE, Ga. and PETERBOROUGH, N.H., Jan. 29, 2018 /PRNewswire/ -- Digirad Corporation, East Hill Management Company, LLC, and Thomas M. Clay (collectively with certain other participants in the solicitation, the "Concerned Aviragen Shareholders Group", the "CAS Group", "we" or "us"), who are significant stockholders of Aviragen Therapeutics, Inc., a Delaware corporation ("Aviragen", "AVIR" or the "Company") (NASDAQ: AVIR), with collective beneficial ownership of approximately 8.3% of AVIR's outstanding shares of common stock, today announced that Institutional Shareholder Services Inc. ("IS

Jan 26, 2018 03:59 pm ET

Aviragen Comments on ISS Report

Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders

Jan 24, 2018 02:55 pm ET

Aviragen Therapeutics Issues Letter to Stockholders

Reiterates Benefits of Proposed Merger with Vaxart

Jan 24, 2018 08:00 am ET

CAS Group Delivers Letter to the Stockholders of Aviragen

SUWANEE, Ga. and PETERBOROUGH, N.H., Jan. 24, 2018 /PRNewswire/ -- Digirad Corporation, East Hill Management Company, LLC and Thomas M. Clay (collectively with certain other participants in the solicitation, the "Concerned Aviragen Shareholders Group", the "CAS Group", "we" or "us"), are significant stockholders of Aviragen Therapeutics, Inc., a Delaware corporation ("Aviragen", "AVIR" or the "Company") (NASDAQ: AVIR), and collectively beneficially own in the aggregate approximately 8.3% of AVIR's outstanding shares of common stock, delivered a letter to the stockholders of AVIR today settin

Jan 11, 2018 07:09 pm ET

Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart

Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders

Nov 29, 2017 07:00 am ET

Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma

ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in...

Nov 02, 2017 07:00 am ET

Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results

ATLANTA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017.

Aug 31, 2017 04:01 pm ET

Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results

ATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017....

Feb 13, 2017 04:01 pm ET

Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir

ATLANTA, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, t...

Feb 02, 2017 04:01 pm ET

Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results

ATLANTA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended December 31, 2016, which is the second quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments....

Feb 01, 2017 04:30 pm ET

Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585

ATLANTA, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its double-blind, placebo-controlled Phase 2a study of BTA585 in adults challenged intranasally with respiratory syncytial virus (RSV). The data indicate there was not a significant reduction in the primary endpoint, which was viral load. The overall safety profile of BTA585 was favorable and consistent across tr...

Jan 26, 2017 04:01 pm ET

Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017

ATLANTA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m. ET to review the Company’s financial results for the three month period ended December 31, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call....

Oct 27, 2016 04:38 pm ET

Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016

ATLANTA, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period ended September 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call....

Oct 10, 2016 09:00 am ET

Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York

ATLANTA, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing burden of human rhinovirus (HRV) infections in at-risk patient populations on Thursday, October 13, 2016 from 8:30 a.m. to 10:30 a.m. ET in New York....

Sep 14, 2016 04:01 pm ET

Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results

ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments....

Sep 13, 2016 07:00 pm ET

Aviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on September 14, 2016

ATLANTA, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference ca...

Sep 07, 2016 09:00 am ET

Aviragen Therapeutics to Present at Upcoming Investor Conferences

ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the following upcoming conferences:...

Sep 06, 2016 06:30 pm ET

Aviragen Therapeutics Announces Inducement Grant for New Employees

ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate of 125,000 shares of the Company's common stock with a per share exercise price of $1.33, the closing price on August 31, 2016. The stock options have a ten-year term and vests over a period of four years, with one-fourth vesting on the first anniversary of the grant date and one-fourth vesting on ...

Sep 06, 2016 05:34 pm ET

Aviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call and Webcast

ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference call and webcast while it concludes discussions involving the accounting treatment for its recent sale of its Inavir® royalty rights to HealthCare Royalty Partners. Aviragen will announce the new time for its conference call and webcast in the next several days....

Sep 01, 2016 09:00 am ET

Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8, 2016

ATLANTA, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference ca...

Jul 12, 2016 07:00 am ET

Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial

ATLANTA, July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development for the treatment and prevention of respiratory syncytial virus (RSV) infections....

Jul 05, 2016 07:00 am ET

Aviragen Therapeutics and Georgia State University Research Foundation Enter Exclusive License and Sponsored Research Agreement to Develop Novel Antiviral Therapies

ATLANTA, July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has entered into an exclusive, worldwide license and sponsored research agreement with Georgia State University Research Foundation (GSURF) to jointly develop and commercialize respiratory syncytial virus (RSV) replication inhibitors discovered by Professor Richard Plemper and his team in the Institute for Biomedical Sciences (IBMS) at Georgia State University....

Jul 01, 2016 04:01 pm ET

Aviragen Therapeutics Announces Inducement Grant for New Employee

ATLANTA, July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company’s Board of Directors granted to Jonas Niaura, Vice President of Business Development and Strategy, an option to purchase an aggregate of 200,000 shares of the Company’s common stock with a per share exercise price of $1.40, the closing price on June 30, 2016. The stock option has a ten-year term and vests over a period of three...

Jun 28, 2016 09:00 am ET

Aviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy

ATLANTA, June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy....

May 26, 2016 04:30 pm ET

Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections

ATLANTA, May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment of RSV infections being conducted in the U.K. This decision emanated from a lab report from one subject showing an increase of a cardiac enzyme level coupled with transient ECG changes, which led to a hospitalization of less than 24 hours. The subject’s ECGs were norma...

May 05, 2016 04:01 pm ET

Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results

ATLANTA, May 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate and clinical developments....

Apr 28, 2016 04:01 pm ET

Aviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016

ATLANTA, April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period ended March 31, 2016 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call....

Ad blocking detected

Atea Pharmaceuticals Inc (OQ:AVIR)

Business Focus: Bio Therapeutic Drugs